- Home
- HRMY vs ARDT Comparison
HRMY vs ARDT Comparison
Compare HRMY & ARDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ARDT
- Stock Information
- Founded
- HRMY 2017
- ARDT 2001
- Country
- HRMY United States
- ARDT United States
- Employees
- HRMY N/A
- ARDT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ARDT
- Sector
- HRMY Health Care
- ARDT
- Exchange
- HRMY Nasdaq
- ARDT NYSE
- Market Cap
- HRMY 2.0B
- ARDT 2.1B
- IPO Year
- HRMY 2020
- ARDT 2024
- Fundamental
- Price
- HRMY $31.89
- ARDT $13.04
- Analyst Decision
- HRMY Strong Buy
- ARDT Buy
- Analyst Count
- HRMY 9
- ARDT 13
- Target Price
- HRMY $54.22
- ARDT $20.77
- AVG Volume (30 Days)
- HRMY 611.9K
- ARDT 252.5K
- Earning Date
- HRMY 08-05-2025
- ARDT 08-13-2025
- Dividend Yield
- HRMY N/A
- ARDT N/A
- EPS Growth
- HRMY 13.13
- ARDT 935.52
- EPS
- HRMY 2.62
- ARDT 1.64
- Revenue
- HRMY $744,852,000.00
- ARDT $6,024,260,000.00
- Revenue This Year
- HRMY $20.10
- ARDT $8.25
- Revenue Next Year
- HRMY $18.01
- ARDT $5.56
- P/E Ratio
- HRMY $12.17
- ARDT $7.89
- Revenue Growth
- HRMY 20.62
- ARDT 8.91
- 52 Week Low
- HRMY $26.47
- ARDT $11.31
- 52 Week High
- HRMY $41.61
- ARDT $20.72
- Technical
- Relative Strength Index (RSI)
- HRMY 36.85
- ARDT N/A
- Support Level
- HRMY $32.39
- ARDT N/A
- Resistance Level
- HRMY $33.42
- ARDT N/A
- Average True Range (ATR)
- HRMY 1.06
- ARDT 0.00
- MACD
- HRMY -0.47
- ARDT 0.00
- Stochastic Oscillator
- HRMY 6.91
- ARDT 0.00
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ARDT ARDENT HEALTH PARTNERS INC
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.